ArticleBMC research notes2025
The influence of the geroprotective cytokine on the transcriptome of young and senescent mesenchymal stem cells.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SenFlag gene signature identifies senescent cells in mouse and human tissues through a conserved core transcriptional program.The EMBO journal · 2026Article
- Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesIncreasing longevity and the growing elderly population necessitate a deeper understanding of aging mechanisms to prolong productive life and improve treatments for age-related diseases linked with cellular senescence. Mesenchymal stem cells (MSCs) are crucial for maintaining tissue homeostasis, but their physiological changes during senescence are not well understood. Growth differentiation factor 11 (GDF11) has emerged as a potential rejuvenation factor, enhancing MSC viability, mobility, and angiogenic functions, which improves outcomes in ischemic models and cardiac repair. This study aims to identify transcriptomic changes in young and senescent MSCs influenced by GDF11, highlighting its potential in MSC-based therapies. DATA DESCRIPTION: To evaluate transcriptomic changes induced by the potential geroprotective factor GDF11, we performed RNA sequencing on four groups of samples: 'young' MSCs (MmC-/GDF11-) and senescent MSCs (MmC+/GDF11-) without the addition of GDF11, as well as 'young' (MmC-/GDF11+) and senescent MSCs (MmC+/GDF11+) with the addition of GDF11. After 10 days of incubation, indexed cDNA libraries for Illumina sequencing were prepared from the samples, and the resulting cDNA library mix was subjected to NovaSeq 6000 sequencing. This paper describes the collection of 16 RNA sequencing samples comprising 4 sets of MSCs. FASTQ files from Illumina sequencing are available in the NCBI Gene Expression Omnibus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.